Quinacrine
- Generic Name
- Quinacrine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30ClN3O
- CAS Number
- 83-89-6
- Unique Ingredient Identifier
- H0C805XYDE
- Background
An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
- Indication
For the treatment of giardiasis and cutaneous leishmaniasis and the management of malignant effusions.
- Associated Conditions
- -
- Associated Therapies
- -
Treatment of Advanced Renal Cell Carcinoma With Quinacrine
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Cleveland BioLabs
- Registration Number
- NCT00574483
- Locations
- 🇺🇸
Community Care Physicians, Albany, New York, United States
🇺🇸ClinWorks Cancer Research Center, Charlotte, North Carolina, United States
Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Cleveland BioLabs
- Target Recruit Count
- 31
- Registration Number
- NCT00417274
CJD (Creutzfeldt-Jakob Disease) Quinacrine Study
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 69
- Registration Number
- NCT00183092
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
PRION-1: Quinacrine for Human Prion Disease
- Conditions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 160
- Registration Number
- NCT00104663
- Locations
- 🇬🇧
National Prion Clinic, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.